Halozyme Therapeutics, Inc.
HALO
$64.66
-$1.88-2.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.12% | 40.79% | 35.22% | 29.55% | 34.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.12% | 40.79% | 35.22% | 29.55% | 34.28% |
| Cost of Revenue | 6.79% | 17.05% | 63.01% | -15.13% | -5.90% |
| Gross Profit | 26.81% | 45.69% | 29.86% | 50.58% | 54.42% |
| SG&A Expenses | 11.75% | 16.53% | 20.57% | 12.34% | 16.93% |
| Depreciation & Amortization | 0.00% | 0.00% | -0.01% | 0.00% | -0.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.45% | 8.03% | 22.91% | -5.04% | 1.30% |
| Operating Income | 33.53% | 72.68% | 48.14% | 73.70% | 79.77% |
| Income Before Tax | 32.58% | 74.06% | 49.78% | 76.14% | 62.29% |
| Income Tax Expenses | 55.43% | 62.37% | 33.99% | 160.99% | 41.22% |
| Earnings from Continuing Operations | 27.89% | 77.12% | 53.72% | 60.46% | 67.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.89% | 77.12% | 53.72% | 60.46% | 67.42% |
| EBIT | 33.53% | 72.68% | 48.14% | 73.70% | 79.77% |
| EBITDA | 30.02% | 62.75% | 40.35% | 61.52% | 65.66% |
| EPS Basic | 38.40% | 85.56% | 58.36% | 63.83% | 74.18% |
| Normalized Basic EPS | 43.48% | 82.35% | 56.34% | 81.90% | 88.66% |
| EPS Diluted | 36.19% | 84.72% | 55.00% | 62.31% | 72.13% |
| Normalized Diluted EPS | 41.04% | 81.14% | 54.43% | 81.01% | 86.86% |
| Average Basic Shares Outstanding | -7.59% | -4.54% | -2.94% | -2.05% | -3.88% |
| Average Diluted Shares Outstanding | -6.00% | -3.92% | -1.74% | -1.57% | -2.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |